Issue No.66: Science Leads and Tech Follows
The Signal
Recently, Mark Cuban wrote a cheque into Galway-based Orreco as part of a $4M Series A extension, for the first proactive approach to use AI to help reduce injury risk.
Orreco is a company founded by scientists who have spent 15 years building a scientific foundation. The team includes 20 PhDs and has published over 400 peer-reviewed papers, analysing athlete data across 16 sports for more than 10,000 elite athletes.
The funding also came with an acquisition: Data Driven Sports Analytics (DDSA), a Melbourne-based computer vision company. Combined, Orreco now offers what it calls “Motion Signal”, which is an AI platform that pulls together external workload data (GPS, video analysis) with internal biomarkers to flag injury risk before soft-tissue damage occurs.
Nine Premier League clubs have piloted the technology, the Philadelphia Flyers demonstrated measurable results, and NBA teams are now in discussions.
This is what happens when science leads and technology follows.
The Strategic Lens
Most sports tech companies start with engineers who build tools and then recruit sports scientists to validate them. Orreco inverted that model and built a company around applied physiology and biostatistics first, then layered AI and computer vision on top.
The result is a fundamentally different credibility profile, allowing them to present peer-reviewed science with technology when talking to teams in elite sport. That matters in a market where practitioners are increasingly sceptical of tech claims it can’t substantiate.
Orreco started with blood biomarker analysis to understand internal load through physiology, and then acquired DDSA. This means they are attempting to integrate the physiology of what’s happening inside the body with how the body is moving. More recently, the tech can now ingest real-time NBA data via Sportradar which positions Orreco as a platform that sits between data sources and practitioner decision-making.
The Funding & Investment Angle
Orreco’s investor profile is a blend of smart money, sports credibility, and operator experience. Cuban’s involvement is particularly notable. As co-owner of the Dallas Mavericks, he’s both an investor and potential customer. An investor who understands the buyer’s perspective often accelerates commercial traction.
Enterprise Ireland’s $1M contribution and the broader context of Irish sports tech is worth noting as Ireland now ranks first in Europe for sports tech VC investment per capita. This reflects a deliberate government strategy, strong university-industry connections, and a cluster effect that’s now self-reinforcing.
The acquisition of DDSA suggests Orreco is now in consolidation mode and will use its platform position to absorb complementary capabilities rather than building everything in-house. This is a mature strategic posture for a company at this stage.
The Credibility Check
The scientific foundation of Orreco’s is its primary differentiator. 400 peer-reviewed papers is genuinely unusual for a commercial sports tech company and the team’s academic credentials provide legitimacy that most competitors can’t match.
The Philadelphia Flyers pilot and Premier League trials offer real-world validation, though detailed outcome data isn’t publicly available. The acquisition of DDSA adds computer vision capability but also introduces integration risk. The key evidence question I am considering, is can Motion Signal demonstrate statistically significant injury reduction across a large enough sample to move from “promising pilot” to “standard of care”?
That data will determine whether Orreco becomes a category leader.
A Personal Perspective
What strikes me about Orreco is the patience, as this company started in 2010 and has building for 15 years. In a sector obsessed with rapid scaling and quick exits, that’s a different philosophy entirely.
As a practitioner, I find the science-first approach genuinely refreshing. Orreco’s 400 papers represents a commitment to building trust and proving claims before making them.
The strategic significance is the shift from reactive to predictive practice. Traditional sports medicine waits for symptoms, whilst Orreco’s model (and the broader category it represents) inverts this through continuous monitoring, pattern recognition, and intervention before injury.
There’s also a professional implication worth noting as Orreco employs 20 PhDs. This signals the intersection, and benefit, of deep domain expertise and technical capability. The next stage would be how to make the best injury preventiion technology accessible to all within sport.
The Takeaway
Orreco demonstrates that science-first companies can attract top-tier investors but it takes time. 15 years isn’t a typical VC timeline. If your innovation requires deep research, find patient capital and build credibility through publication, not just press releases.
Ireland’s sports tech cluster is real and worth attention as it is repeatedly combining talent, government support, and proximity to European football.
Finally, predictive injury prevention shifts the value proposition and highlights again the increasing skill set for practitioners. Those who can interpret AI-generated risk signals and translate them into actionable interventions will be more valuable than those who wait for injuries to present.
The tension between rigorous evidence and rapid scaling is real but patience seems to be paying off.
I would love to know your thoughts on this Issue by commenting below.
Thanks for reading! Nic x